GBA Presents: RADIO SAVANT-!

Vz I have in your column here some ugly ducklings--

ARE YOU OUT OF ALL OF THESE BUY RECOMMENDATIONS?

SFWL $8---> $6.25

PZZA $78--> $72

SNAP $10.60---> $9.60

SNAP $10 calls expired worthless.

SIRI $3.69--> $3.69

LRN $42----->$42


Let me start over with some of your good ideas.

Back In ABB?

ASRT-! This was the last call of yours I really liked.:strong:

any others? :)
 

Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up
Zacks Equity Research
Tue, May 16, 2023, 7:44 AM EDT
In this article:
  • KOD


Kodiak Sciences KOD reported first-quarter 2023 loss per share of $1.35, wider than the Zacks Consensus Estimate of a loss of $1.28. The company reported a loss of $1.83 per share in the year-ago quarter.

The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues.

Despite missing earnings estimate, shares of Kodiak jumped 12.6% on Monday due to strong pipeline progress. Kodiak expects to file a single biological license application (BLA) for tarcocimab in the four major retinal vascular disease indications. In the past year, shares of KOD have plunged 13.7% compared with the industry’s 6.1% fall.

0d50192261ee8b2902ddc6ccc7706a28
 
vanzandt said:
PZZA was a 74 reccy
You too have called out snap about a dozen times... and I actually saved the readers before earnings with a CLASSIC read.
More...



Let me give u my 2 cents on ASRT--

-> This stock really moved when you recommended it I'm going to say high $5's --> to now.

--> I came away from a CC extremely impressed with the frankness of the CEO

--> I think Price targets should be around $10?

--> It is under priced now.

--> There is a reason. These guys are buying Spectrum a stk I know well. As far as I know they are in the process of completing this deal.

And shareholders were concerned that ASRT had overpaid... Understandable.

What they are buying from SSPI--> Rolvedon

There had been concerns Rolvedon sales would not grow fast enough to warrant the valuation Assertio is paying.

--> Those concerns were prety much put to bed when SSPI reported
54% sequential growth in Rolvedon sales.

So we should close this deal and the stk should elevate.
 
You must log in or register to reply here.
Back
Top